|Day Low/High||3.65 / 4.00|
|52 Wk Low/High||4.63 / 9.91|
- New architectures enable targeting of any chosen location in the genome with very high precision
Clear strategy with new management, organizational structure and clinical capabilities will drive Sangamo's industry-leading scientific platform into human studies
SB-525 is one of four programs in the Company's newly focused clinical portfolio of in vivo genomic therapies for rare diseases
On Track to File Investigational New Drug Application for Hemophilia A Program by End of 2016
Dr. Edward Conner Appointed as Senior Vice President and Chief Medical Officer and Curt Herberts Promoted to Newly Created Role of Senior Vice President and Chief Business Officer
ZFN-Mediated Genome Editing Programs in Sickle Cell Disease and Beta-Thalassemia Will Move from Biogen to Bioverativ in Line with the Spin-Off Company's Focus on Rare Blood Disorders
The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 918,730 share increase in total short interest for Sangamo BioSciences Inc , to 8,679,778, an increase of 11.84% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Shares of Omeros fell almost 10% after analysts' downgraded the biotech.
The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,057,847 share decrease in total short interest for Sangamo BioSciences Inc , to 7,636,100, a decrease of 12.17% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Scientists Present Preclinical Data Demonstrating High Levels of Factor VIII Protein Expression from Proprietary Therapeutic AAV cDNA Construct at World Federation of Hemophilia 2016 World Congress
Investors in Sangamo BioSciences Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Company Advances Third In Vivo Protein Replacement Platform™ (IVPRP) Program into Clinical Development
Leadership Transition Underlines Evolution from a Platform Company to a Therapeutic Product Company
New Histologic Data Demonstrate Disease Correction in Tissues after ZFP Therapeutic Treatment in Mouse Model of MPS I
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.